OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI has acquired biotech software startup Orchestra Bio to integrate its AI agents and team into OpenAI's life sciences initiatives. The acquired technology will support Rosalind, an AI model and workbench tool designed to help researchers plan experiments and manage drug discovery operations.
Why it matters
This acquisition highlights how major AI labs are expanding their proprietary software and tools deeper into high-value vertical industries like pharmaceuticals, rather than just competing with traditional tech companies.
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced on its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind , its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in